Immunology– tag –

Strategic Review: Rare Disease, GI, Vaccines, and Innovation Takeda has transformed itself into a global biopharma leader through acquisitions such as Nycomed in 2011 (expanding GI/respiratory reach in Europe), Shire in 2018 (rare diseas...

Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Over the last decade, it...

Strategic Review: From Opdivo to Next-Gen Modalities BMS is known as a pioneer in immuno-oncology, with the development of Opdivo (nivolumab) and Yervoy (ipilimumab). Over the past decade, the company has expanded aggressively into new m...

A comprehensive review published in the June 2025 issue of Nature Biotechnology summarizes the current status of personalized mRNA cancer vaccine development. Neoantigen-based mRNA vaccines, tailored to individual patients' tumor mutatio...